News from sponsors

Opdivo is reimbursed as of 1st of January in Lung (NSCLC), RCC (renal) and Hodgkin in monotherapy, as well as in melanoma in combination with Yervoy.

More information can be read in the article of BMS (PDF)

www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf